STOK — Stoke Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1623526 ·
Last close
$26.41
Market Cap
$1.73B
52W High
$40.22
52W Low
$22.05
ADV30
1,146,393
Next earnings
2026-10-29

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 9,325,000 — -65,429,000 -61,618,000 393,966,000 110,004,000 48,419,000
Mar 2026 6,229,000 — -53,418,000 -50,003,000 443,277,000 155,659,000 48,400,000
Dec 2025 1,402,000 — -61,439,000 -57,934,000 418,434,000 84,220,000 65,977,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-210,307,000
Investing CF
$-11,558,000
Financing CF
$248,742,000
CapEx
$-5,412,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.45
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-682,980,000
Inventory
—
Receivables
$10,076,000
ST Investments
$211,916,000
EBIT TTM
$-257,601,000
Pretax Income TTM
$-243,199,000
Interest Exp TTM
—
Analysts
13

Yahoo Snapshot (yfinance, live)

Total Revenue
$28,210,000
EBITDA
$-255,844,000
Free Cash Flow
$-125,546,624
Enterprise Value
$1,418,617,344
Total Cash
$319,187,008
Total Debt
$1,922,000
Shares Out
65,406,268
Trailing EPS
$-3.81
Book Value
$5.44
ROE
-73.6%
ROA
-42.0%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 184,420,000 -20,590,000 -6,885,000 418,434,000 65,977,000 352,457,000 45,585,000
Dec 2024 36,555,000 -101,372,000 -88,981,000 271,555,000 42,534,000 229,021,000 -86,851,000
Dec 2023 8,780,000 -114,773,000 -104,699,000 228,342,000 68,777,000 159,565,000 -81,067,000
Dec 2022 12,405,000 -104,356,000 -101,067,000 256,067,000 71,218,000 184,849,000 -31,866,000

TTM Snapshot

Revenues TTM
$27,588,000
NetIncome TTM
$-207,902,000
OpCashFlow TTM
—
Assets (Latest)
$393,966,000
Forward EPS
$-4.09

Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)

max pain strike: $15.00 · spot: $26.69 · call volume: 26 · put volume: 7
Expected Move to 2027-02-19: ±$6.60 (24.73%) — implied range $20.09 – $33.29 · ATM straddle on $25.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
RARE Ultragenyx Pharmaceutical Inc. $1.70B $16.70 —
SUPN Supernus, Inc. $1.69B $29.04 —
BRVE Braveheart Bio, Inc. $1.69B $18.78 —
SDGR Schrodinger, Inc. $1.68B $25.66 —
ZYME Zymeworks Inc. $1.78B $25.84 —

News headlines (Yahoo Finance, 1h cache)

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-11-17 21:01 · Yahoo
Stoke Therapeutics (STOK) Faces A Valuation Test Following Weaker Nine Month Results
2026-11-07 04:26 · Yahoo
Stoke Therapeutics to Present at Upcoming Investor Conferences in November
2026-11-03 13:00 · Yahoo
Stoke Therapeutics (STOK) Stock Price Faces Q3 Results Cash Burn Question
2026-10-31 22:11 · Yahoo
Stoke Therapeutics, Inc. Q3 2026 Earnings Call Summary
2026-10-30 12:30 · Yahoo
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates
2026-10-29 22:05 · Yahoo
Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates
2026-10-29 20:01 · Yahoo
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates
2026-10-22 12:00 · Yahoo
Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
2026-10-12 12:00 · Yahoo
FDA Alignment on Zorevunersen Endpoints Could Be A Game Changer For Stoke Therapeutics (STOK)
2026-10-09 23:09 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.